BioSpace News Archive

CureVac N.V. (NASDAQ:CVAC) , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid announced today that the underwriters of its previously announced public offering, which closed on February 1, 2021, have exercised in full their option to purchase an additional 750,000 of its common shares

Baxter Reports Fourth-quarter sales of $3.2 billion increased 5% on a reported basis, 3% on a constant currency basis and 2% on an operational basis 1 Fourth-quarter U.S. GAAP earnings per share (EPS) were $0.33 and adjusted EPS were $0.80 Full-year revenue of $11.7 billion increased 3% on both a reported and constant currency basis and 2% on an operational basis

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Food and Drug Administration (FDA) has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.

Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory failure Randomized, double-blind, placebo-controlled study expected to enroll ~1,000 patients across global sites with results expected in Q4 2021 Company to host conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT

A study published in the journal Pediatrics expands validation evidence for a new screening tool that directly engages preschool-age children during clinic visits to assess their early literacy skills.

Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that it will present three late-breaker abstracts at the 17th annual WORLDSymposium, a research conference dedicated to lysosomal diseases being held virtually February 8-12, 2021

TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Shawn Tomasello to its Board of Directors.

Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that Eric Ostertag , M.D., Ph.D., Poseida Therapeutics’ Chief Executive Officer, will participate in a fireside chat on February 12, 2021

Dalrada Financial Corp. (OTCQB: DFCO, “Dalrada”) is pleased to announce that Dalrada Heath has finalized the Company’s acquisition of U.S.-based Pacific Stem Cells, LLC.

Dalan Animal Health, a pioneer in insect vaccination, announced the issuance of a Notice of Allowance for U.S. Patent Application 15/747,252 “Edible Vaccination Against Microbial Pathogens.” The original technology was developed at the University of Helsinki, Finland, by Dr. Dalial Freitak and Dr. Heli Salmela.